Print Page

Letters to Healthcare Providers
 
FDA Requires a Warning about Guillain-Barré Syndrome (GBS) be Included in the Prescribing Information for Shingrix (Letter to Healthcare Professionals)
 
 
 
Attachment:
  1. FDA Requires a Warning about Guillain-Barré Syndrome (GBS) be Included in the Prescribing Information for Shingrix  
Related Information:
Australia: Shingrix vaccine and very rare risk of Guillain-Barré Syndrome Posted 2024-10-29
The United States: FDA requires a warning about Guillain-Barré Syndrome (GBS) be... Posted 2021-03-25
 
back